# Graybug Vision

Graybug Vision is an other based in Redwood City, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Redwood City, United States
- **Region:** North America
- **Address:** Redwood City, CA, United States
- **Founded:** 2010
- **Assets under management:** Undisclosed
- **Website:** graybug.vision

## Regulatory record

- **Reports private funds:** No

## About

Graybug Vision (Nasdaq: GRAY) is a pharmaceutical company founded in 2011. It focuses on developing treatments for chronic retinal and optic nerve diseases. Based in Redwood City, California.

## Sectors

- Digital Health
- Healthcare Services

## People

- David Guyer — Co-Founder & CEO
- Anthony Adamis — Co-Founder & Chief Scientific Officer
- Geoffrey H. Gurtner — Board Member

## Questions

### Who runs investment decisions at Graybug Vision?

Graybug Vision is a clinical-stage biopharmaceutical company run by CEO David Guyer and CSO Anthony Adamis. Investment in the company's pipeline is managed by its board of directors and executive team rather than a family office structure, as Graybug is a public company.

### How does Graybug Vision generate drug development capital?

Graybug Vision raised venture funding from institutional investors including Blackstone Life Sciences and The Baupost Group before completing a $137M SPAC merger in 2021 (per SEC filings, 2021). The company has not disclosed additional large capital raises since then.

### What is Graybug Vision's drug delivery approach?

Graybug's technology uses a microparticle-based depot system that releases active drug over months from a single injection. This is intended to treat retinal diseases like wet AMD and diabetic macular edema with reduced injection frequency compared to current standard-of-care monthly injections.

### Has Graybug Vision approved any commercial drugs?

No. As of mid-2026, Graybug Vision has no commercially approved products. Its lead candidate GB-102 has completed Phase 2 trials but a Phase 3 program for diabetic macular edema was paused in 2024 following a dose-limiting toxicity signal.

## Related profiles

- [Wiregrass Construction Company](https://altss.com/profile/wiregrass-construction-company)
- [Neltjeberg Bay Enterprises LLC](https://altss.com/profile/neltjeberg-bay-enterprises-llc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/graybug-vision

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology